Bexson Biomedical Announces Publication of Peer-Reviewed Paper Describing Novel Ketamine Formulation


Bexson’s primary formulation involves ketamine, which blocks the NMDA receptor, a fundamental unit in pain signaling. Ketamine is already given by physicians in the management of severe pain by intravenous infusion, but healthcare providers are limited by current formulations, which reduces access and increases the cost of care. This new formulation is designed to be paired with a small, portable pump device to provide patients and providers with a convenient, non-opioid therapy for the management of chronic and acute pain.

The Bexson researchers have also confirmed that their formulation technique can be applied to other drug molecules in need of innovation or redirection, including many psychedelics and empathogens. Subcutaneous administration via portable devices and metered injection pens can innovate the delivery of psychedelic and non-psychedelic drugs.

“We believe our technology will solve many of the challenges facing psychedelic medicine,” said jeffrey becker, MD, scientific director of Bexson. “This peer-reviewed publication also highlights novel properties of our psychedelic formulations, which may provide reliability, convenience, rapid dosage adjustment, and reduced gastrointestinal side effects. We are thrilled with the results we are seeing.”

“It has been gratifying to establish a new approach to subcutaneous formulations that can enable fine tissue tuning without compromising potency,” said Jason Wallach, PhD, Senior Consultant in Medicinal Chemistry at Bexson. “We’re also successfully applying this new strategy to a wide variety of existing drugs and scaffolds, and we’re just beginning to understand just how far this repurposing technology can reach.”

Bexson Biomedical, Inc.. is a research-stage company developing BB106, a ketamine therapy for pain management and mental health disorders. Pain after surgery is a $12 billion market and a leading cause of opioid abuse and addiction. The company also applies its proprietary delivery platform to several psychedelic and non-psychedelic compounds. Visit at:

SOURCEBexson Biomedical


Comments are closed.